The North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market would witness market growth of 7.7% CAGR during the forecast period (2023-2030).
Anal, oral, and vaginal sex are all possible ways to spread Chlamydia trachomatis. It can also be transferred from a mother to a newborn child during childbirth. Women and young adults (15 to 24) are more likely to suffer from this medical condition. The prevalence of men and women experiencing infertility brought on by Chlamydia Trachomatis infection is generally increasing, therefore increasing internationally Artificial Insemination (AI) or Intrauterine Insemination (IUI) treatments.
The Chlamydia Trachomatis Test Model includes sub-segments for Chlamydia Trachomatis Nucleic Acid Amplification Tests (NAATs) and additional Chlamydia Trachomatis tests, such as Immunochromatography, Direct Fluorescent Antibody (DFA), Indirect Fluorescent Antibody (IFA), and Enzyme Linked Immuno Sorbent Assay (ELISA).
The two most prevalent reported sexually transmitted diseases (STI) in Canada are Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), according to a recent study issued by the Canadian government in May 2023. Rates of reported cases of CT increased by 33.1% between 2010 and 2019, whereas rates of NG climbed by 181.7%. The number of CT and NG cases reported in Canada in 2019 was 139,386 and 35,443, respectively. These numbers translate to rates of 370.8 and 94.3 per 100,000 people. In 2019, those from the Canadian territories (Yukon, Northwest Territories, and Nunavut) had the highest rates of CT, with 757.0, 1,901.0, and 3,876.8 cases per 100,000 individuals, respectively. Since 2010, the Northwest Territories and Nunavut have had the highest rates of NG, exceeding 1,000 cases per 100,000 persons in 2019. The regional market is anticipated to expand as STI cases are increasing gradually.
The US market dominated the North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $756.7 million by 2030. The Canada market is experiencing a CAGR of 10.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 9.2% during (2023 - 2030).
Based on Product, the market is segmented into Assays & Kits, and Instruments & Analyzers. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Testing Type, the market is segmented into Lab Tests, and PoC Tests. Based on Technology, the market is segmented into Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market is Projected to reach USD 2.8 Billion by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, ZeptoMetrix LLC (Antylia Scientific), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Bayer AG, Qiagen N.V. and Siemens AG.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Assays & Kits
- Instruments & Analyzers
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Others
By Testing Type
By Technology
- Isothermal Nucleic Acid Amplification Technology
- Polymerase Chain Reaction
- Immunodiagnostics
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Becton, Dickinson and Company
- ZeptoMetrix LLC (Antylia Scientific)
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Thermo Fisher Scientific, Inc.
- Bayer AG
- Qiagen N.V.
- Siemens AG
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, by Product
1.4.2 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, by End User
1.4.3 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, by Testing Type
1.4.4 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, by Technology
1.4.5 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product
4.1 North America Assays & Kits Market by Country
4.2 North America Instruments & Analyzers Market by Country
Chapter 5. North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User
5.1 North America Diagnostic Laboratories Market by Country
5.2 North America Hospitals & Clinics Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type
6.1 North America Lab Tests Market by Country
6.2 North America PoC Tests Market by Country
Chapter 7. North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology
7.1 North America Isothermal Nucleic Acid Amplification Technology Market by Country
7.2 North America Polymerase Chain Reaction Market by Country
7.3 North America Immunodiagnostics Market by Country
7.4 North America Others Market by Country
Chapter 8. North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country
8.1 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market
8.1.1 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product
8.1.2 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User
8.1.3 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type
8.1.4 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology
8.2 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market
8.2.1 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product
8.2.2 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User
8.2.3 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type
8.2.4 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology
8.3 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market
8.3.1 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product
8.3.2 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User
8.3.3 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type
8.3.4 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology
8.4 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market
8.4.1 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product
8.4.2 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User
8.4.3 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type
8.4.4 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology
Chapter 9. Company Profiles
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Trials & Approvals:
9.1.6 SWOT Analysis
9.2 Becton, Dickinson, and Company
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Product Launches and Product Expansions:
9.2.6 SWOT Analysis
9.3 ZeptoMetrix LLC (Antylia Scientific)
9.3.1 Company Overview
9.3.2 SWOT Analysis
9.4 Danaher Corporation
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Trials & Approvals:
9.5.6 SWOT Analysis
9.6 Hologic, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Thermo Fisher Scientific, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 SWOT Analysis
9.8 Bayer AG
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Qiagen N.V.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 SWOT Analysis
9.10. Siemens AG
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 SWOT Analysis
TABLE 1 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2019 - 2022, USD Million
TABLE 2 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2023 - 2030, USD Million
TABLE 3 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2019 - 2022, USD Million
TABLE 4 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2023 - 2030, USD Million
TABLE 5 North America Assays & Kits Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Assays & Kits Market by Country, 2023 - 2030, USD Million
TABLE 7 North America Instruments & Analyzers Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Instruments & Analyzers Market by Country, 2023 - 2030, USD Million
TABLE 9 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2019 - 2022, USD Million
TABLE 10 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2023 - 2030, USD Million
TABLE 11 North America Diagnostic Laboratories Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Diagnostic Laboratories Market by Country, 2023 - 2030, USD Million
TABLE 13 North America Hospitals & Clinics Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Hospitals & Clinics Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2019 - 2022, USD Million
TABLE 18 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2023 - 2030, USD Million
TABLE 19 North America Lab Tests Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Lab Tests Market by Country, 2023 - 2030, USD Million
TABLE 21 North America PoC Tests Market by Country, 2019 - 2022, USD Million
TABLE 22 North America PoC Tests Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2019 - 2022, USD Million
TABLE 24 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2023 - 2030, USD Million
TABLE 25 North America Isothermal Nucleic Acid Amplification Technology Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Isothermal Nucleic Acid Amplification Technology Market by Country, 2023 - 2030, USD Million
TABLE 27 North America Polymerase Chain Reaction Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Polymerase Chain Reaction Market by Country, 2023 - 2030, USD Million
TABLE 29 North America Immunodiagnostics Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Immunodiagnostics Market by Country, 2023 - 2030, USD Million
TABLE 31 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 33 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country, 2023 - 2030, USD Million
TABLE 35 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2019 - 2022, USD Million
TABLE 36 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2023 - 2030, USD Million
TABLE 37 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2019 - 2022, USD Million
TABLE 38 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2023 - 2030, USD Million
TABLE 39 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2019 - 2022, USD Million
TABLE 40 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2023 - 2030, USD Million
TABLE 41 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2019 - 2022, USD Million
TABLE 42 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2023 - 2030, USD Million
TABLE 43 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2019 - 2022, USD Million
TABLE 44 US Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2023 - 2030, USD Million
TABLE 45 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2019 - 2022, USD Million
TABLE 46 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2023 - 2030, USD Million
TABLE 47 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2019 - 2022, USD Million
TABLE 48 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2023 - 2030, USD Million
TABLE 49 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2019 - 2022, USD Million
TABLE 50 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2023 - 2030, USD Million
TABLE 51 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2019 - 2022, USD Million
TABLE 52 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2023 - 2030, USD Million
TABLE 53 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2019 - 2022, USD Million
TABLE 54 Canada Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2023 - 2030, USD Million
TABLE 55 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2019 - 2022, USD Million
TABLE 56 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2023 - 2030, USD Million
TABLE 57 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2019 - 2022, USD Million
TABLE 58 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2023 - 2030, USD Million
TABLE 59 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2019 - 2022, USD Million
TABLE 60 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2023 - 2030, USD Million
TABLE 61 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2019 - 2022, USD Million
TABLE 62 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2023 - 2030, USD Million
TABLE 63 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2019 - 2022, USD Million
TABLE 64 Mexico Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2023 - 2030, USD Million
TABLE 65 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2019 - 2022, USD Million
TABLE 66 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2023 - 2030, USD Million
TABLE 67 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2019 - 2022, USD Million
TABLE 68 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2023 - 2030, USD Million
TABLE 69 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2019 - 2022, USD Million
TABLE 70 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2023 - 2030, USD Million
TABLE 71 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2019 - 2022, USD Million
TABLE 72 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2023 - 2030, USD Million
TABLE 73 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2019 - 2022, USD Million
TABLE 74 Rest of North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2023 - 2030, USD Million
TABLE 75 Key Information – Abbott Laboratories
TABLE 76 Key information – Becton, Dickinson and Company
TABLE 77 Key Information – ZeptoMetrix LLC
TABLE 78 Key Information – Danaher Corporation
TABLE 79 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 80 Key Information – Hologic, Inc.
TABLE 81 Key Information – Thermo Fisher Scientific, Inc.
TABLE 82 Key Information – Bayer AG
TABLE 83 Key Information – Qiagen N.V.
TABLE 84 Key Information – Siemens AG
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market, 2019 - 2030, USD Million
FIG 3 Key Impacting Factors chlamydia trachomatis/neisseria gonorrhoeae (CT/NG) testing market
FIG 4 Porter’s Five Forces Analysis - Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market
FIG 5 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Product, 2022
FIG 6 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Product, 2030
FIG 7 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product, 2019 - 2030, USD Million
FIG 8 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by End User, 2022
FIG 9 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by End User, 2030
FIG 10 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by End User, 2019 - 2030, USD Million
FIG 11 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Testing Type, 2022
FIG 12 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Testing Type, 2030
FIG 13 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type, 2019 - 2030, USD Million
FIG 14 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Technology, 2022
FIG 15 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Technology, 2030
FIG 16 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Technology, 2019 - 2030, USD Million
FIG 17 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Country, 2022
FIG 18 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market share by Country, 2030
FIG 19 North America Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Abbott Laboratories
FIG 21 SWOT Analysis: Becton, Dickinson and company
FIG 22 SWOT Analysis: Becton, Dickinson and company
FIG 23 SWOT Analysis: Danaher Corporation
FIG 24 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 25 Swot Analysis: Hologic, Inc.
FIG 26 Swot Analysis: Thermo Fisher Scientific, Inc.
FIG 27 Swot Analysis: Bayer AG
FIG 28 Swot Analysis: Qiagen N.V.
FIG 29 SWOT Analysis: Siemens AG